TY - JOUR
T1 - Separate Effect of Perioperative Recombinant Human Factor VIIa Administration and Packed Red Blood Cell Transfusions on Midterm Survival in Lung Transplantation Recipients
AU - Huddleston, Stephen J.
AU - Jackson, Scott
AU - Kane, Kathleen
AU - Lemke, Nicholas
AU - Shaffer, Andrew W.
AU - Soule, Matthew
AU - Hertz, Marshall
AU - Shumway, Sara
AU - Qi, Stephen
AU - Perry, Tjorvi
AU - Kelly, Rosemary
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/11
Y1 - 2020/11
N2 - Objective: The purpose of this study was to determine the relationship between blood product transfusion, with or without recombinant human activated factor VIIa, and survival after lung transplantation. Design: Retrospective analysis of a single center with follow-up out to 6 years post-transplantation. Setting: Single-center academic lung transplantation program. Participants: The study comprised 265 adult patients who underwent single or bilateral sequential lung transplantation from March 2011 to June 2017. Interventions: Overall survival using Kaplan-Meier curves was compared among the following 3 cohorts: those not transfused with blood products, those transfused with blood products, and those given blood products and recombinant human activated factor VIIa. Cox proportional hazards regression was used to estimate hazard ratios (HRs), confidence intervals (CIs), and p values. Measurements and Main Results: Seventy-eight patients received no packed red blood cell transfusions, 149 received packed red blood cell transfusions, and 38 received both packed red blood cell transfusions and recombinant human activated factor VII. Packed red blood cell transfusion was associated with an increased risk of mortality that did not reach statistical significance (HR 2.168, CI 0.978-4.805; p = 0.057). Additional packed red blood cells beyond 15 U were associated with worsened survival (HR 1.363, CI 1.137-1.633; p = 0.001), but recombinant human activated factor VIIa did not increase the risk of mortality. Conclusion: Blood product transfusion during and after lung transplantation is associated with decreased survival, especially with large-volume transfusions. Survival is not worse with recombinant human activated factor VIIa administration, but additional studies are needed to determine whether recombinant human activated factor VIIa administration reduces the need for blood product transfusions.
AB - Objective: The purpose of this study was to determine the relationship between blood product transfusion, with or without recombinant human activated factor VIIa, and survival after lung transplantation. Design: Retrospective analysis of a single center with follow-up out to 6 years post-transplantation. Setting: Single-center academic lung transplantation program. Participants: The study comprised 265 adult patients who underwent single or bilateral sequential lung transplantation from March 2011 to June 2017. Interventions: Overall survival using Kaplan-Meier curves was compared among the following 3 cohorts: those not transfused with blood products, those transfused with blood products, and those given blood products and recombinant human activated factor VIIa. Cox proportional hazards regression was used to estimate hazard ratios (HRs), confidence intervals (CIs), and p values. Measurements and Main Results: Seventy-eight patients received no packed red blood cell transfusions, 149 received packed red blood cell transfusions, and 38 received both packed red blood cell transfusions and recombinant human activated factor VII. Packed red blood cell transfusion was associated with an increased risk of mortality that did not reach statistical significance (HR 2.168, CI 0.978-4.805; p = 0.057). Additional packed red blood cells beyond 15 U were associated with worsened survival (HR 1.363, CI 1.137-1.633; p = 0.001), but recombinant human activated factor VIIa did not increase the risk of mortality. Conclusion: Blood product transfusion during and after lung transplantation is associated with decreased survival, especially with large-volume transfusions. Survival is not worse with recombinant human activated factor VIIa administration, but additional studies are needed to determine whether recombinant human activated factor VIIa administration reduces the need for blood product transfusions.
KW - activated factor VII
KW - blood transfusion
KW - coagulopathy
KW - lung allocation score
KW - lung transplant
KW - outcomes
KW - primary graft dysfunction
KW - redo surgery
KW - surgical
UR - http://www.scopus.com/inward/record.url?scp=85088819648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088819648&partnerID=8YFLogxK
U2 - 10.1053/j.jvca.2020.05.038
DO - 10.1053/j.jvca.2020.05.038
M3 - Article
C2 - 32718888
AN - SCOPUS:85088819648
SN - 1053-0770
VL - 34
SP - 3013
EP - 3020
JO - Journal of Cardiothoracic and Vascular Anesthesia
JF - Journal of Cardiothoracic and Vascular Anesthesia
IS - 11
ER -